Aquestive Therapeutics (AQST) Return on Capital Employed (2018 - 2026)

Aquestive Therapeutics' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 46.96% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 234.0% year-over-year to 46.96%; the TTM figure through Mar 2026 stood at 46.96% (up 234.0% YoY), while the FY2025 annual figure was 85.28%, down 3446.0% from the prior year.
• Return on Capital Employed was 46.96% for Q1 2026 at Aquestive Therapeutics, up from 62.12% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 13.85% in Q2 2024 to a low of 281.76% in Q4 2022.
• Historically, Return on Capital Employed has averaged 94.3% across 5 years, with a median of 62.12% in 2025.
• The sharpest annual moves came in 2022 and 2023: Return on Capital Employed sank 19856 bps in 2022, then jumped 24413 bps in 2023.
• A 5-year view of Return on Capital Employed shows it stood at 281.76% in 2022, then surged by 87 bps to 37.64% in 2023, then gained by 6 bps to 35.44% in 2024, then tumbled by 75 bps to 62.12% in 2025, then grew by 24 bps to 46.96% in 2026.
• The last three Return on Capital Employed figures came in at 46.96% (Q1 2026), 62.12% (Q4 2025), and 54.14% (Q3 2025), per Business Quant data.